SPR741, an Antibiotic Adjuvant, Potentiates theIn VitroandIn VivoActivity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
Abstract
Acinetobacter baumanniiis responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR)A. baumanniistrain. In standardin vitroassays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2017
- Source ID
- 10.1128/aac.01239-17
Entities
People
- Alexandria A. Reinhart
- Daniel V Zurawski
- Jonathan P. Shearer
- Michael J Pucci
- Rania Abu-taleb
- Samandra T. Demons
- Stuart D. Tyner
- Troy Lister
- Yonas A. Alamneh
- Yuanzheng Si
Organizations
- Congressionally Directed Medical Research Programs
- Walter Reed Army Institute of Research